Chronic Hand Eczema: Prevalence and Clinical Complexity

CHRONIC HAND ECZEMA
(CHE) IS DEFINED AS
HAND ECZEMA THAT³

Lasts more than
3
months

OR

Has returned
2x
or more within a year

IT'S ESTIMATED
TO AFFECT ~26 MILLION ADULTS
IN THE U.S.^4,5

The problem

CHE is a multifactorial, heterogeneous, relapsing Disease^2,3,6

with multiple subtypes that often overlap

As a result, it can have a number of clinical presentations. Itch and pain are the most debilitating symptoms for patients and are often what they seek relief from.⁷

DID YOU
KNOW?

More than half of patients with CHE
have 2 or more subtypes⁶

CHE can present as⁸:

COMPLETE LIST OF CHE SUBTYPES^†

Etiological Subtypes³

Morphological Subtypes³

^†Based on 2022 European Society of Contact Dermatitis guideline.

The Need

CHE keeps going,
even when topical corticosteroids are not enough³

CHE is a long-term condition with multiple presentations. Topical corticosteroids may not be suitable for long-term treatment as they may have either an inadequate response and can have limitations with long-term use.

The Solution

The first and only FDA-approved treatment to address the needs of adult patients with moderate-to-severe CHE.^1,2

Find out how you can Find out how you can Treat CHE
differently

Find out how you can Find out how you can Treat CHE
differently

INDICATION

ANZUPGO is indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.

Limitations of Use: Use of ANZUPGO in combination with other JAK inhibitors or potent immunosuppressants is not recommended.

Please see full Prescribing Information and Medication Guide.

IMPORTANT SAFETY INFORMATION AND INDICATION

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Serious Infections: ANZUPGO may increase the risk of infections. Eczema herpeticum was observed in a subject treated with ANZUPGO. Serious and sometimes fatal infections have been reported in patients receiving oral or topical JAK inhibitors. Avoid use of ANZUPGO in patients with an active or serious infection. Consider the risks and benefits of treatment prior to initiating ANZUPGO in patients with chronic or recurrent infection, who have been exposed to tuberculosis, with a history of a serious or an opportunistic infection, or with underlying conditions that may predispose them to infection.

Closely monitor patients for the development of signs and symptoms of infection during and after treatment with ANZUPGO. Interrupt treatment with ANZUPGO if a patient develops a serious infection. Do not resume ANZUPGO until the infection resolves or is adequately treated.

Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical trials with ANZUPGO. If a patient develops herpes zoster, consider interrupting ANZUPGO treatment until the episode resolves.

The impact of ANZUPGO on chronic viral hepatitis reactivation is unknown. Consider viral hepatitis screening and monitoring for reactivation in accordance with clinical guidelines before starting therapy and during therapy with ANZUPGO. If signs of reactivation occur, consult a hepatitis specialist. ANZUPGO is not recommended for use in patients with active hepatitis B or hepatitis C.

Non-melanoma Skin Cancers: Non-melanoma skin cancers, including basal cell carcinoma, have been reported in subjects treated with ANZUPGO. Periodic skin examinations of the application sites are recommended for all patients, particularly those with risk factors for skin cancer. Advise patients to avoid sunlamps and minimize exposure to sunlight by wearing sun-protective clothing or using broad-spectrum sunscreen.

Immunizations: Prior to ANZUPGO treatment, complete all age-appropriate vaccinations as recommended by current immunization guidelines, including herpes zoster vaccinations. Avoid vaccination with live vaccines immediately prior to, during, and immediately after ANZUPGO treatment.

Potential Risks Related to JAK Inhibition: It is not known whether ANZUPGO may be associated with the observed or potential adverse reactions of JAK inhibition. In a large, randomized, postmarketing safety trial of an oral JAK inhibitor in combination with methotrexate in rheumatoid arthritis (RA), patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of all-cause mortality, including sudden cardiovascular death, major adverse cardiovascular events (MACE), overall thrombosis, deep venous thrombosis (DVT), pulmonary embolism (PE), and malignancies (excluding non-melanoma skin cancer) were observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. ANZUPGO is not indicated for use in RA.

Treatment with oral and topical JAK inhibitors has been associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides.

Adverse Reactions

Adverse reactions reported in ≤1% of subjects were application site pain, paresthesia, pruritus, erythema, and bacterial skin infections, including finger cellulitis, paronychia, other skin infections, leukopenia, and neutropenia.

Use in specific populations

Lactation: To minimize potential infant exposure, advise breastfeeding women to avoid direct contact with the nipple and surrounding area immediately after applying ANZUPGO to the hands and/or wrists.

Please see full Prescribing Information and Medication Guide.

Read more Collapse

*See full Terms, Conditions, and Eligibility Rules.

REFERENCES:

1. ANZUPGO. Prescribing information. LEO Pharma Inc. 2. Dubin C, et al. Ther Clin Risk Manag. 2020;16:1319-1332. doi:10.2147/TCRM.S292504 3. Thyssen JP, et al. Contact Dermatitis. 2022;86(5):357-378. doi:10.1111/cod.14035 4. Lee GR, et al. Dermatol Ther. 2019;32(3):e12840. doi:10.1111/dth.12840 5. Agner, et al. J Eur Acad Dermatol Venereol. 2015;29(12):2417-2422. doi:10.1111/jdv.13308 6. Zalewski A, et al. J Clin Med. 2023;12(13):4198. doi:10.3390/jcm12134198 7. Grant L, et al. Adv Ther. 2020;37(2):692-706. doi:10.1007/s12325-019-01164-5

*See full Terms, Conditions, and Eligibility Rules.